sábado, 18 de marzo de 2017

West Nile Virus Seroprevalence, Connecticut, USA, 2000–2014 - Volume 23, Number 4—April 2017 - Emerging Infectious Disease journal - CDC

West Nile Virus Seroprevalence, Connecticut, USA, 2000–2014 - Volume 23, Number 4—April 2017 - Emerging Infectious Disease journal - CDC

Volume 23, Number 4—April 2017

Research Letter

West Nile Virus Seroprevalence, Connecticut, USA, 2000–2014

Megan E. Cahill, Yi Yao, David Nock, Philip M. Armstrong, Theodore G. Andreadis, Maria A. Diuk-Wasser, and Ruth R. MontgomeryComments to Author 
Author affiliations: Yale University School of Public Health, New Haven, Connecticut, USA (M.E. Cahill)Yale University School of Medicine, New Haven (Y. Yao, D. Nock, R.R. Montgomery)The Connecticut Agricultural Experiment Station, New Haven (P.M. Armstrong, T.G. Andreadis)Columbia University, New York, New York, USA (M.A. Diuk-Wasser)


West Nile virus (WNV) infection is mainly asymptomatic but can be severe in elderly persons. As part of studies on immunity and aging in Connecticut, USA, we detected WNV seroconversion in 8.5% of nonimmunosuppressed and 16.8% of immunosuppressed persons. Age was not a significant seroconversion factor. Our findings suggest that immune factors affect seroconversion.
Since the 1999 emergence of West Nile virus (WNV) in North America, >43,000 cases of disease and 1,884 deaths have been reported (1); overall infections are estimated at ≈3 million (2). Although WNV infections can be asymptomatic, they can also cause severe neuroinvasive disease, especially among infants, immunocompromised persons, and elderly persons (3). Control of WNV infection involves innate immune pathways that mediate initial recognition and regulation of viral replication and adaptive immune responses that provide long-term protection (3). Spatial distribution analysis and mosquito surveillance studies have confirmed that WNV is endemic to Connecticut, USA (1,4).
We compared seroprevalence and demographics for 890 nonimmunosuppressed and 173 immunosuppressed adults enrolled in a study on immunity in aging (approved by the Human Investigations Committee of Yale University) (5) with those of symptomatic WNV case-patients reported to the Connecticut Department of Health (DPH) during 2000–2014. DPH-reported symptomatic case-patients (n = 116) sought medical attention and had a positive WNV laboratory test result (1). None of the asymptomatic participants were reported to DPH as WNV case-patients. Immunosuppressed participants followed an immunosuppressive medication regimen or had a diagnosis of rheumatoid arthritis (5). For all participants, we assessed previous exposure to WNV by immunoblot for WNV envelope protein (6). Seroconversion to WNV was distinguished from cross-reactivity to other flaviviruses by rescreening all positive serum against a recombinant WNV-specific mutant envelope protein that lacks the conserved cross-reactive fusion loop epitope (7).
We compared demographic characteristics of participant groups by using the Student t-test for continuous variables and χ2 and Fisher exact tests for categorical variables; p<0.05 indicated statistical significance. Analysis was completed with SAS software version 9.3 (SAS Institute, Cary, NC, USA) and Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
Immunoblot detected evidence of WNV exposure in 76 (8.5%) of the 890 nonimmunosuppressed participants (Table). These seropositive participants reported neither symptoms nor diagnosis of WNV infection and are considered to have had asymptomatic infections. Timing of asymptomatic infections could not be determined, but antibodies against WNV are durable and do not differ between asymptomatic and symptomatic adults (8).
Although age is a critical risk factor for severe WNV infection (3,9), the mean age of seropositive and seronegative nonimmunosuppressed participants did not differ significantly (Table). The rate of asymptomatic seroconversion did not vary significantly among the 890 persons in 3 age groups: <35 years (42/421), 35–65 years (7/121), and >65 years (27/348) (p = 0.338). Seroconversion rates did not differ significantly by patient sex but were significantly elevated among those in self-identified Hispanic groups (p<0.0001), possibly because of different exposure histories. The similar age distribution among asymptomatic seroconverters suggests that the observed age-associated susceptibility to clinically apparent disease may result from other factors, including individual host factors and dysregulation in immune responses (6,10).
Among 173 immunosuppressed adults, 29 (16.8%) showed evidence of exposure to WNV (Table), resulting in 2.16 times the odds of positive immunoblot result than for nonimmunosuppressed adults (76/890, 8.5%; p = 0.002). Seroconversion rates among immunosuppressed persons did not differ statistically according to sex or age. The seroconversion rate was higher among immunosuppressed Hispanics (16/40, 40.0%) than non-Hispanics (13/132, 9.8%) (p<0.0001). Because the immunosuppression status of DPH-reported case-patients was not available, we could not further explore a role for immunosuppression in the occurrence of WNV infection among these patients. Immunosuppression carries unique risks for infectious diseases; thus, the higher rate of seroconversion among immunosuppressed participants may be a consequence of underlying medical conditions or medication regimens.
The mean age for asymptomatic seropositive adults, nonimmunosuppressed and immunosuppressed, was lower than that for DPH-reported symptomatic case-patients (Table; p = 0.0004). The 2 groups did not vary significantly according to sex (p = 0.30). Because racial data for DPH-reported case-patients was not available, no comparison by race was possible. Comparison of geocoded household locations of all study participants and DPH case-patients showed an overlapping distribution of nonimmunosuppressed and immunosuppressed asymptomatic seroconverters and DPH case-patients (Technical Appendix Figure). Although only a surrogate for location where infection was acquired, this mapping provides no support for localized pockets of increased disease susceptibility.
We provide evidence of WNV exposure in Connecticut among 1,063 adults who differed by age, sex, race, and immunosuppression status. Among nonimmunosuppressed asymptomatic participants, age was not a significant factor with regard to WNV seroconversion. However, mean age of symptomatic case-patients was older than that of asymptomatic seropositive participants, indicating that age remains a factor in disease susceptibility (9). Age has a well-documented role in decreased immune cell function and increased susceptibility to infectious diseases, including WNV (9,10); dysregulation of immune responses with elevated cytokine levels may contribute to development of severe disease. The higher WNV seroprevalence among immunosuppressed adults strongly suggests a key role for immune factors in seroconversion.
Ongoing research seeks to further define the immune system attributes that lead to increased risk for higher WNV disease severity; active areas of interest include genomic, transcriptional, and immune- and age-related variable responses (6,8,9). In addition to environmental conditions that affect vector abundance, our study suggests that individual variation, such as immune status, may be a key driver for susceptibility to infection and disease severity and for differing seroconversion rates among neighbors.
Ms. Cahill is a candidate for a PhD degree in the epidemiology of microbial diseases at the Yale School of Public Health. She is interested in biology and viral disease susceptibility.


We are grateful to Barbara Siconolfi, Sui Tsang, and Qiong Zhang for sample collection and helpful discussions. We thank Michael Diamond for his kind gift of recombinant WNV-specific mutant envelope protein.
This work was supported in part by awards from the National Institutes of Health (HHS N272201100019C and AI08992), the Centers for Disease Control and Prevention (U50/CCU116806-01-1), the US Department of Agriculture (58- 6615-1-218, CONH00768, and CONH00773), and the Multistate Research Project (NE1043).
All procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Certain data used in this study were obtained from the Connecticut DPH, which approved this study.


  1. Centers for Disease Control and Prevention. West Nile virus, final cumulative maps & data for 1999–2014 [cited 2016 Apr 6]. http://www.cdc.gov/westnile/statsMaps/cumMapsData.html
  2. Petersen LRCarson PJBiggerstaff BJCuster BBorchardt SMBusch MPEstimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect2013;141:5915DOIPubMed
  3. Suthar MSPulendran BSystems analysis of West Nile virus infection. Curr Opin Virol2014;6:705DOIPubMed
  4. Diuk-Wasser MABrown HEAndreadis TGFish DModeling the spatial distribution of mosquito vectors for West Nile virus in Connecticut, USA.Vector Borne Zoonotic Dis2006;6:28395DOIPubMed
  5. Dunne DWShaw ABockenstedt LKAllore HGChen SMalawista SEet al. Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults. PLoS One2010;5:e11343DOIPubMed
  6. Qian FGoel GMeng HWang XYou FDevine Let al. Systems immunology reveals markers of susceptibility to West Nile virus infection. Clin Vaccine Immunol2015;22:616DOIPubMed
  7. Chabierski SBarzon LPapa ANiedrig MBramson JLRichner JMet al. Distinguishing West Nile virus infection using a recombinant envelope protein with mutations in the conserved fusion-loop. BMC Infect Dis2014;14:246DOIPubMed
  8. Qian FThakar JYuan XNolan MMurray KOLee WTet al. Immune markers associated with host susceptibility to infection with West Nile virus.Viral Immunol2014;27:3947DOIPubMed
  9. Montgomery RRAge-related alterations in immune responses to West Nile virus infection. Clin Exp Immunol2017;187:2634DOIPubMed
  10. Shaw ACGoldstein DRMontgomery RRAge-dependent dysregulation of innate immunity. Nat Rev Immunol2013;13:87587DOIPubMed


Technical Appendix

Cite This Article

DOI: 10.3201/eid2304.161669

No hay comentarios:

Publicar un comentario